ABN Amro Investment Solutions Takes Position in Royalty Pharma PLC $RPRX

ABN Amro Investment Solutions purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 1st quarter, Holdings Channel.com reports. The firm purchased 32,130 shares of the biopharmaceutical company’s stock, valued at approximately $1,541,000.

Several other hedge funds have also recently added to or reduced their stakes in RPRX. LM Advisors LLC purchased a new position in shares of Royalty Pharma in the fourth quarter worth about $26,000. Blue Trust Inc. grew its stake in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 437 shares in the last quarter. Lloyd Advisory Services LLC. purchased a new stake in Royalty Pharma during the 4th quarter valued at about $30,000. Private Trust Co. NA raised its holdings in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in Royalty Pharma by 34.7% in the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 282 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RPRX has been the topic of several recent research reports. Citigroup boosted their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Finally, Morgan Stanley upped their target price on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average target price of $56.57.

Insider Buying and Selling

In other news, CFO Terrance P. Coyne sold 64,399 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total value of $3,476,258.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares in the company, valued at approximately $10,165,559. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 427,800 shares of company stock worth $23,333,723. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Trading Down 0.3%

NASDAQ:RPRX opened at $58.83 on Friday. Royalty Pharma PLC has a 12-month low of $34.08 and a 12-month high of $59.72. The firm has a market cap of $33.88 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 10.45 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a fifty day moving average price of $55.60 and a 200 day moving average price of $49.21.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $630.58 million for the quarter, compared to analyst estimates of $881.69 million. Sell-side analysts anticipate that Royalty Pharma PLC will post 5.18 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Friday, August 14th. Royalty Pharma’s dividend payout ratio (DPR) is 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.